Latest Breaking News On - Intermediate care - Page 24 : comparemela.com

 E-Mail Aachen, Germany and Hennigsdorf/Berlin, Germany, May 4, 2021 - German University Hospital Uniklinik RWTH Aachen ( Uniklinik RWTH Aachen ) and diagnostics company SphingoTec GmbH ( SphingoTec ) today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and management of patients suffering from severe COVID-19, in need for escalated intensive care treatment (1). A team lead by the clinical researchers at Uniklinik RWTH Aachen has shown that high bio-ADM levels indicate the severity of the acute respiratory distress syndrome (ARDS), the subsequent need for organ support, and poor outcomes in severely ill COVID-19 patients. Bioactive Adrenomedullin (bio-ADM) is a hormone regulating endothelial function and has been previously validated in over 35.000 patients with diseases where endothelial dysfunction plays a key role, such as sepsis, septic shock, cardiogenic shock, and acute heart failure.

San diegoUnited statesBioactive adrenomedullinAndreas bergmannSphingotec gmbhGernot marxDepartment of operative intensive care medicineUniversity hospitalGerman university hospital uniklinikNexus dx incUniversity hospital uniklinikOperative intensive care medicineIntermediate careSimont pCritically ill patientsBiologically active adrenomedullin